Description

Meningococcal Group B Vaccine

Meningococcal disease is a potentially deadly infection that often presents with symptoms similar to a cold in its early stages, making it difficult to recognize. This infection can quickly lead to severe health issues, including meningitis, long-term disabilities, and even death. Therefore, receiving the B meningococcal vaccine is a critical measure for preventing this dangerous disease. Understanding the importance of this vaccine, its modes of transmission, and high-risk groups can help protect you and your family.

Bacterial meningitis caused by Neisseria meningitidis can lead to invasive meningococcal disease. Its early symptoms are difficult to diagnose and can easily be confused with the common cold.

• Fever
• Headache
• Fatigue
• Skin rash

 

Meningococcal infection can be life-threatening or result in long-term disabilities

• One out of every ten patients dies from meningococcal infection.
• One out of every five patients may experience severe long-term disabilities, including brain damage, hearing loss, and limb loss.

 

Modes of Transmission

• Sneezing, coughing
• Close physical contact
• Sharing food and drinks
• Meningococcal bacteria can survive in the throat and nose.
• Approximately one-tenth of the population are long-term carriers.
• Teenagers and young adults have the highest carrier rates.

 

High-risk Groups

Children and Teenager

• Children aged 5 or below : Immature immune systems
• Teenager aged 15-25 : Changes in social behavior combined with close physical contact increase the risk

 

Meningococcal Group B Vaccine

• Approved by the US FDA and the European Medicines Agency (EMA)
• The only Meningococcal Group B Vaccine available for infants and young children below 10 years of age
• Contains 4 antigens for broader protection

 

Recommended vaccination schedule

Age		2-5 months	6-11 months	12-23 months	2 years old or above
Dose	Primary Dose	2 doses	2 doses	2 doses	2 doses
	Booster Dose	Administered between 12 and 15 months, with a minimum interval of 6 months after the primary dose	Administered between 13 and 23 months, with a minimum interval of 2 months after the primary dose	Administered within 12 to 23 months after the primary dose	According to recommendations, a booster dose should be considered to reduce the risk of meningococcal disease infection

 

 

Instructions for use:

• Must be used on or before the expiration date.
• Please show your confirmation information, order number, registered full name and phone number for verification

 

Terms and Conditions:

• This voucher is only valid for Trinity Medical Centre.
• The vaccine must be given within 90 days after purchase of this voucher. This voucher can be used at Central, Causeway Bay or Tsim Sha Tsui Trinity Medical Centre. The validity period will not be extended by this voucher.
• This voucher is non-refundable and cannot be redeemed for full or partial cash.
• You must bring this ticket to the front desk when you register.
• This voucher cannot be used with any other special offers and promotions.
• This voucher is not valid after expiration.
• If this voucher is lost or stolen, we will not accept any liability and will not provide any reissue in such case.
• If you have any questions, please call 2192 7022 or email tmc@trinitymedical.com.hk
• Trinity Medical Centre reserves the right to amend the above Terms and Conditions without prior notice. In case of any disputes, Trinity Medical Centre reserves all rights for final decision